Prolonged US-Iran War and Drug Price Cuts: Triple Blow to Pharmaceutical Industry Profitability
High Exchange Rates, Soaring Oil Prices, and Drug Price Cuts
As the prolonged war between the United States and Iran continues to drive up exchange rates and oil prices across the board, concerns are mounting over the profitability of the domestic pharmaceutical industry, with the government's drug price reduction policy adding further pressure.
According to the industry on April 3, major pharmaceutical companies are shifting to emergency management mode in response to escalating short- and long-term financial burdens, including soaring exchange rates and oil prices due to the Middle East conflict, as well as the drug price reduction policy.
The most urgent issue is the exchange rate. The KRW-USD exchange rate has risen by approximately 5.7%, from last year's average of 1,423 won to around 1,512 won as of the previous day. Based on last year's annual reports, if the current exchange rate is maintained, it is estimated that all major pharmaceutical companies will incur additional procurement costs ranging from several billion to tens of billions of won, depending on the raw materials they purchase.
GC Green Cross, for example, spent 275.6 billion won on overseas plasma procurement for key blood products such as Aliglo and Albumin, and is now expected to face about 15.7 billion won in additional costs due to the higher exchange rate. Chong Kun Dang purchased a total of 226.5 billion won in raw materials, including choline alfoscerate (56.9 billion won) for its cognitive function enhancer Gliatilin and carvedilol (16.8 billion won) for its hypertension drug Dilatrend. Considering an industry average import ratio of 70% for raw materials, the company is expected to face nearly 9 billion won in foreign exchange losses.
Hanmi Pharmaceutical spent 78.1 billion won on imported pharmaceutical ingredients such as Fesium powder, used in gastrointestinal medicines, resulting in an estimated increase of about 4.5 billion won in procurement costs. Daewoong Pharmaceutical spent 47.8 billion won on key imported raw materials, such as 9.9 billion won for mosapride (a digestive drug) and 8.7 billion won for Olmetec tablets (an antihypertensive), and if the high exchange rate persists, it will face about 2.7 billion won in additional costs compared to last year. Yuhan Corporation is also expected to see roughly 2.3 billion won in increased procurement costs, based on its 40.4 billion won in imported raw materials for products such as Atacand tablets (13.3 billion won, antihypertensive) and Almagate (5.2 billion won, antacid).
There are also growing concerns about direct and indirect damage from rising oil prices. International oil prices have surged more than 60%, from last year's level of $60 per barrel (about 90,750 won) to over $100 per barrel (about 151,250 won) as of April 3. In addition to overall increases in maritime logistics costs, there is heightened uncertainty regarding the supply of naphtha, a key feedstock for medical sub-materials such as IV bags and packaging. Korea is highly dependent on Middle Eastern naphtha, much of which passes through the Strait of Hormuz. Therefore, prolonged instability in the Middle East could directly lead to disruptions in the supply of naphtha, causing higher costs for medical disposables and packaging, and ultimately production disruptions.
Recently, on social networking services, there have been opinions that the supply of basic materials derived from petroleum may become unstable due to the Middle East war, potentially disrupting the supply of chemical drugs with complex organic compound structures, such as Tylenol and Aspirin. In response, Johnson & Johnson and Bayer, which sell Tylenol and Aspirin, stated, "We do not adjust supply prices in the short term due to temporary issues," and added, "The likelihood of short-term price increases due to raw material supply disruptions or cost increases is low." Johnson & Johnson did announce that it will raise the supply price of Tylenol by 10% starting in May, but clarified that this is not a reflection of raw material price fluctuations.
The government's revised drug price reduction plan is further increasing downward pressure on industry profitability. The Ministry of Health and Welfare has decided to lower the drug price calculation rate for generic medicines from the previous 53.55% of the original to 45%, representing a practical 16% decline in sales prices. According to an analysis by the Emergency Countermeasures Committee of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, the annual revenue loss for the entire pharmaceutical sector is estimated to reach between 760 billion won and 780 billion won if the drug price cut is implemented.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
According to the committee, the average operating profit per company is expected to fall by about 32% compared to previous levels. The government has granted a grace period for drug price reductions only to innovative and quasi-innovative pharmaceutical companies to encourage R&D investment. However, according to the committee's survey, pharmaceutical companies facing increased cost burdens and shrinking profitability have begun implementing self-help measures, including cutting R&D investment by an average of 16% and reducing new facility investment by more than 20%.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.